Docoh
Loading...

CYCC Cyclacel Pharmaceuticals

Employees

Data from SEC filings
Employee count

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM


(a) The Annual Meeting of Cyclacel Pharmaceuticals, Inc. (the “Company”) was held on June 15, 2021 (the “Annual Meeting”).

(b) Proposals Submitted to the Company’s Stockholders

The following proposals were submitted to the holders of the Company’s shares of common stock and voted upon at the Annual Meeting: (i) the reelection of three Class 3 directors to the Company’s board of directors, (ii) the ratification of the selection of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021, (iii) the approval of an amendment to the Company’s 2018 Equity Incentive Plan, and (iv) the approval, on an advisory basis, of the executive compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement.

Proposals Submitted to Holders of Common Stock

(i) Votes of the common stockholders regarding the election of the Class 3 director nominees were as follows:

Votes ForVotes
Withheld
Broker
Non-Votes
Paul McBarron2,654,603332,4133,075,832
Dr. Christopher Henney2,941,17545,8413,075,832
Dr. Robert Spiegel2,941,82945,1873,075,832


Based on the votes set forth above, Paul McBarron, Dr. Christopher Henney, and Dr. Robert Spiegel were duly reelected as Class 3 directors of the Company to serve until the 2024 annual meeting of stockholders or until their respective successors are elected and qualified or until their earlier resignation or removal.

(ii) Votes of the common stockholders regarding the ratification of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021 were as follows:

Votes ForVotes
Against
AbstentionsBroker
Non-Votes
6,007,33336,73218,7830


Based on the votes set forth above, the selection of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021 was ratified.

(iii) Votes of the common stockholders regarding the approval of an amendment to the Company’s 2018 Equity Incentive Plan were as follows:

Votes ForVotes
Against
AbstentionsBroker
Non-Votes
2,493,130423,45170,7350


Based on the votes set forth above, the proposal to approve an amendment to the Company’s 2018 Equity Incentive Plan was approved.

(iv) Votes of the common stockholders, on an advisory basis, regarding the executive compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement, were as follows:

Votes ForVotes
Against
AbstentionsBroker
Non-Votes
2,381,303463,919141,7943,075,832


Based on the votes set forth above, the proposal to approve the executive compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement, was approved on an advisory basis.